EPOCH方案治疗初治外周T细胞淋巴瘤的临床效果  

Clinical effect of EPOCH regimen in the treatment of primary treatment of peripheral T cell lymphoma

作　　者：张静 颜丽华 许伟 徐志阳 丁现超 ZHANG Jing;YAN Li-hua;XU Wei;XU Zhi-yang;DING Xian-chao(Hematology Department,Zhengzhou Yihe Hospital,Zhengzhou 450018,China)

机构地区：[1]郑州颐和医院血液内科,河南郑州450018

出　　处：《临床医学研究与实践》2020年第17期28-29,共2页Clinical Research and Practice

摘　　要：目的 分析EPOCH方案治疗初治外周T细胞淋巴瘤(PTCL)的临床效果.方法 将80例初治PTCL患者按照治疗方案不同分为对照组和观察组,各40例.对照组采用CHOP方案治疗,观察组采用EPOCH方案治疗.比较两组的临床疗效、生存情况和安全性.结果 观察组的治疗有效率为82.50%,高于对照组的60.00%(P<0.05).观察组1、3年的总生存率均高于对照组(P<0.05).观察组的不良反应总发生率低于对照组(P<0.05).结论 EPOCH方案治疗初治PTCL的效果显著,可延长患者的生存时间,且毒副反应较轻.Objective To analyze the clinical effect of EPOCH regimen in the treatment of primary treatment of peripheral T cell lymphoma(PTCL).Methods According to different treatment regimens,80 patients with primary treatment of PTCL were divided into control group and observation group,with 40 cases in each group.The control group was treated with CHOP regimen,while the observation group was treated with EPOCH regimen.The clinical efficacy,survival and safety of the two groups were compared.Results The effective rate of treatment in the observation group was 82.50%,which was higher than 60.00%in the control group(P<0.05).The 1-year and 3-year survival rates of the observation group were higher than those of the control group(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion EPOCH regimen has significant effect on primary treatment of PTCL,which can prolong the survival time of patients,and has less side effects.

关 键 词：外周T细胞淋巴瘤 EPOCH方案 CHOP方案 

分 类 号：R733.1[医药卫生—肿瘤]